Pluri (PLUR) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLUR Pluri Inc PLUR
25 GF Score
Price $1.83
GF Value $6.54
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pluri Net Loan?

Net Loan only applies to banks and insurance companies.

PLUR
25GF Score
Pluri Inc PLUR
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pluri (PLUR) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of $1.83 is trading 72% below its estimated GF Value™ of $6.54. GuruFocus considers Pluri to be Possible Value Trap.

Key valuation signals for PLUR:

  • Net Loan:
  • GF Value™: $6.54 vs. price of $1.83 (72% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for PLUR

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.83
Price
$6.54
GF Value